CHRS
Coherus BioSciences Inc
NASDAQ: CHRS · HEALTHCARE · BIOTECHNOLOGY
$1.74
-1.69% today
Updated 2026-04-29
Market cap
$262.31M
P/E ratio
—
P/S ratio
6.22x
EPS (TTM)
$-1.56
Dividend yield
—
52W range
$1 – $3
Volume
1.3M
Coherus BioSciences Inc (CHRS) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.90M | $2.75M | $31.11M | $30.04M | $190.11M | $1.56M | $1.56M | $356.07M | $475.82M | $326.55M | $211.04M | $257.24M | $266.96M | $42.17M |
| Revenue growth (YoY) | — | +44.9% | +1030.7% | -3.4% | +532.8% | -99.2% | +0.0% | +22783.7% | +33.6% | -31.4% | -35.4% | +21.9% | +3.8% | -84.2% |
| Cost of revenue | $34.89M | $31.28M | $78.22M | $212.68M | $254.44M | $160.53M | $3.23M | $17.08M | $37.67M | $57.59M | $70.08M | $158.99M | $117.55M | $13.81M |
| Gross profit | $-32.99M | $-28.53M | $-47.12M | $-182.64M | $-64.33M | $-158.97M | $-1.68M | $338.99M | $438.16M | $268.96M | $140.96M | $98.25M | $149.41M | $28.36M |
| Gross margin | -1737.1% | -1037.0% | -151.5% | -608.0% | -33.8% | -10216.9% | -107.9% | 95.2% | 92.1% | 82.4% | 66.8% | 38.2% | 56.0% | 67.2% |
| R&D | $34.89M | $31.28M | $78.22M | $213.06M | $254.44M | $162.39M | $110.24M | $94.19M | $142.76M | $363.11M | $199.36M | $109.44M | $93.34M | $108.89M |
| SG&A | $5.53M | $7.46M | $17.56M | $36.05M | $51.60M | $71.30M | $94.18M | $132.54M | $135.28M | $161.01M | $187.98M | $174.72M | $139.54M | $100.60M |
| Operating income | $-38.52M | $-35.99M | $-64.68M | $-219.07M | $-115.93M | $-232.14M | $-204.42M | $107.77M | $156.32M | $-263.86M | $-256.88M | $-203.20M | $-111.67M | $-181.13M |
| Operating margin | -2028.3% | -1308.4% | -207.9% | -729.2% | -61.0% | -14918.8% | -13137.3% | 30.3% | 32.9% | -80.8% | -121.7% | -79.0% | -41.8% | -429.5% |
| EBITDA | $-31.28M | $-47.94M | $-82.72M | $-222.04M | $-116.81M | $-225.34M | $-204.42M | $111.03M | $161.84M | $-260.69M | $-255.58M | $-193.94M | $60.94M | $-170.20M |
| EBITDA margin | -1647.3% | -1742.6% | -265.9% | -739.1% | -61.4% | -14481.7% | -13137.3% | 31.2% | 34.0% | -79.8% | -121.1% | -75.4% | 22.8% | -403.6% |
| EBIT | $-31.50M | $-48.34M | $-83.39M | $-223.91M | $-119.81M | $-228.73M | $-207.65M | $107.77M | $156.87M | $-264.14M | $-259.28M | $-197.73M | $55.66M | $-174.12M |
| Interest expense | $1.51M | $5.29M | $3.90M | $33000.00 | $7.98M | $9.55M | $9.68M | $17.60M | $21.17M | $22.96M | $32.47M | $40.54M | $27.16M | $9.00M |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-33.02M | $-53.63M | $-87.13M | $-223.26M | $-127.34M | $-238.17M | $-209.34M | $89.83M | $132.24M | $-287.10M | $-291.75M | $-237.89M | $28.51M | $-170.29M |
| Net income growth (YoY) | — | -62.4% | -62.5% | -156.2% | +43.0% | -87.0% | +12.1% | +142.9% | +47.2% | -317.1% | -1.6% | +18.5% | +112.0% | -697.4% |
| Profit margin | -1738.7% | -1949.7% | -280.1% | -743.2% | -67.0% | -15306.6% | -13453.7% | 25.2% | 27.8% | -87.9% | -138.2% | -92.5% | 10.7% | -403.8% |